Barclays PLC Has $1.45 Million Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Barclays PLC lifted its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 14.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,563 shares of the company’s stock after buying an additional 8,346 shares during the quarter. Barclays PLC owned about 0.13% of Enliven Therapeutics worth $1,453,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ELVN. KLP Kapitalforvaltning AS bought a new position in Enliven Therapeutics in the fourth quarter valued at approximately $97,000. ExodusPoint Capital Management LP acquired a new position in shares of Enliven Therapeutics in the 4th quarter valued at $200,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Enliven Therapeutics by 14.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock worth $233,000 after purchasing an additional 1,275 shares during the last quarter. Invesco Ltd. grew its stake in shares of Enliven Therapeutics by 3.5% during the fourth quarter. Invesco Ltd. now owns 15,072 shares of the company’s stock worth $339,000 after purchasing an additional 508 shares during the period. Finally, Intech Investment Management LLC bought a new stake in Enliven Therapeutics in the fourth quarter valued at about $367,000. 95.08% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Joseph P. Lyssikatos sold 12,500 shares of the business’s stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $20.61, for a total value of $257,625.00. Following the sale, the insider now directly owns 1,002,688 shares of the company’s stock, valued at approximately $20,665,399.68. The trade was a 1.23 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $20.41, for a total value of $66,332.50. Following the transaction, the chief financial officer now owns 13,000 shares of the company’s stock, valued at approximately $265,330. This trade represents a 20.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 66,751 shares of company stock worth $1,331,288 in the last 90 days. Corporate insiders own 29.20% of the company’s stock.

Enliven Therapeutics Stock Up 3.3 %

Shares of NASDAQ ELVN opened at $20.51 on Friday. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $30.03. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -10.79 and a beta of 1.03. The company’s fifty day moving average is $19.17 and its 200-day moving average is $22.38.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million for the quarter. On average, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright raised their target price on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, March 21st.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.